Alnylam Pharmaceuticals (ALNY) Current Assets (2009 - 2026)

Alnylam Pharmaceuticals' Current Assets history runs 18 years deep, the most recent figure standing at $4.2 billion for Q1 2026.

• Quarterly Current Assets rose 29.1% year-over-year to $4.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 billion (up 29.1% YoY) and the FY2025 annual result came in at $4.1 billion, up 22.92% from the prior year.
• Current Assets was $4.2 billion for Q1 2026 at Alnylam Pharmaceuticals, up from $4.1 billion in the prior quarter.
• Across five years, Current Assets topped out at $4.2 billion in Q1 2026 and bottomed at $2.5 billion in Q2 2022.
• A 5-year average of $3.1 billion and a median of $3.0 billion in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets declined 9.3% — and 2026, when it climbed 29.1%.
• Alnylam Pharmaceuticals' Current Assets stood at $2.7 billion in 2022, then increased by 10.79% to $3.0 billion in 2023, then advanced by 10.48% to $3.3 billion in 2024, then grew by 22.92% to $4.1 billion in 2025, then increased by 4.16% to $4.2 billion in 2026.
• Business Quant data shows ALNY's Current Assets at $4.2 billion in Q1 2026, $4.1 billion in Q4 2025, and $4.0 billion in Q3 2025.